NY-SCEPTER-PARTNERS
Scepter Partners, a leading direct investment and merchant banking platform for sovereign wealth and large cap family offices, announced the appointment of one of its founders, financier Rayo Withanage as Group Chief Executive Officer. In this role, Mr. Withanage will be responsible for leading the expansion and profitability of the Group. HH Prince Abdul Ali Yil Kabier shall continue as chairman of the Board of Stakeholders. Regarding Mr. Withanage’s appointment, HH Prince Abdul Ali, a scion of the Brunei Royal Family, commented, “We are honored to continue under the inspiration and leadership of Mr. Withanage. As he moves to a more executive role, he will drive the financial and strategic dimension of our business, which has the full support of over $14 billion in assets represented by Scepter’s core investors."
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151009005800/en/
Mr. Withanage was named by Euromoney as one of the most influential financiers in the Middle East and Asia, responsible for founding the BMB Group as "the industry's most exclusive commercial multi-family office." Trained as an M&A lawyer, he went into direct investments and began his career as a successful investor in emerging markets before becoming the head of the private investment offices of the co-founders of BMB. Under his leadership and majority ownership, BMB became the first commercial multi-family office of ruling families to unify investors from the Middle East & Asia. Mr. Withanage has an LLB in Law & a BA in Government from The University of Auckland and an MSc from the London School of Economics.
In 2015, the core investors of BMB decided to spin out their assets and combine resources with a number of sovereign and institutional investors to form Scepter. The move was the result of a desire by core investors to develop an institution with significantly more capital, syndication and merchant banking capabilities than a traditional family office. Scepter is now run by Anthony Steains and the former Blackstone Asia Advisory Partners Team. BMB was also refocused to be a specialist advisor and co-investor for Forbes 500 families. BMB, with offices in Bermuda and London, is now led by independent management under its CEO, Rahula Withanage.
About Scepter
Scepter is a standing syndicate of ruling families, ultra-high-net-worth industrialists and sovereign wealth funds. Headquartered in Bermuda with offices in New York and representative offices in London and Beijing, Scepter was founded to acquire large cap assets with a focus in natural resources, infrastructure, real estate and media and telecommunications. As a principal investor, Scepter is supported by the discretionary assets of its core stakeholders and a syndicate of investors who have combined resources to invest in off-market large cap transactions globally. For more information, please visit www.scepterpartners.com .
Legal Notice
Scepter Partners is a principal investor that does not require authorization by the Financial Conduct Authority or the Securities and Exchange Commission or by any financial services regulatory body. Scepter does not have any products open for third party investors. Nothing in this announcement is intended to be, or should be construed as an invitation, offer or inducement to any person or entity to engage in any investment activity.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151009005800/en/
Contact:
Hill+Knowlton Strategies
Joe Millsap, 1-212-885-0464
Joe.Millsap@hkstrategies.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom